益生菌：肠道屏障、免疫调节与肝损伤 - Suppr

Suppr

超能文献

Probiotics: intestinal gatekeeping, immunomodulation, and hepatic injury.

作者信息

Versalovic James

出版信息

Hepatology. 2007 Sep;46(3):618-21. doi: 10.1002/hep.21916.

DOI:10.1002/hep.21916

PMID:17879361

Abstract

摘要

相似文献

Probiotics: intestinal gatekeeping, immunomodulation, and hepatic injury.益生菌：肠道屏障、免疫调节与肝损伤

Hepatology. 2007 Sep;46(3):618-21. doi: 10.1002/hep.21916.

Probiotics and liver disease.益生菌与肝脏疾病

J Clin Gastroenterol. 2008 Jul;42 Suppl 2:S80-4. doi: 10.1097/MCG.0b013e318169c44e.

Gut microbiota and probiotics in chronic liver diseases.肠道微生物群和益生菌与慢性肝病。

Dig Liver Dis. 2011 Jun;43(6):431-8. doi: 10.1016/j.dld.2010.10.015. Epub 2010 Dec 16.

Effect of probiotics on intestinal barrier function.益生菌对肠道屏障功能的影响。

Ann N Y Acad Sci. 2009 May;1165:183-9. doi: 10.1111/j.1749-6632.2009.04059.x.

Role of probiotic bacteria in sepsis.益生菌在败血症中的作用。

Hepatology. 2008 Apr;47(4):1422; author reply 1422-3. doi: 10.1002/hep.22111.

Health, probiotics, and inflammation.健康、益生菌与炎症。

J Clin Gastroenterol. 2008 Sep;42 Suppl 3 Pt 2:S177-8. doi: 10.1097/MCG.0b013e31817eedc4.

Probiotics: which and when?益生菌：哪些益生菌以及何时使用？

Dig Dis. 2008;26(2):175-82. doi: 10.1159/000116776. Epub 2008 Apr 21.

Gut flora-based therapy in liver disease? The liver cares about the gut.基于肠道菌群的肝病治疗？肝脏关注肠道。

Hepatology. 2004 May;39(5):1197-200. doi: 10.1002/hep.20220.

Probiotics in health and diseases.健康与疾病中的益生菌。

J Assoc Physicians India. 2001 Jul;49:735-41.

[Probiotics in the era of evidence-based medicine. Humbug or significant therapy?].[循证医学时代的益生菌。是骗局还是重要疗法？]

MMW Fortschr Med. 2002 Nov 28;144(48):6-8.

引用本文的文献

Expression and predictive value of serum core fucosylated low molecular weight kininogen and alpha-galactosylated antibodies in patients with hepatic fibrosis.血清核心岩藻糖基低分子量激肽原和α-半乳糖基抗体在肝纤维化患者中的表达及其预测价值。

Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2024 Jun 28;49(6):903-913. doi: 10.11817/j.issn.1672-7347.2024.240018.

Gut Microbiota: Target for Modulation of Gut-Liver-Adipose Tissue Axis in Ethanol-Induced Liver Disease.肠道微生物群：调节乙醇诱导的肝脏疾病中肠-肝-脂肪组织轴的靶点。

Mediators Inflamm. 2022 May 20;2022:4230599. doi: 10.1155/2022/4230599. eCollection 2022.

Dysbiosis, Host Metabolism, and Non-communicable Diseases: Trialogue in the Inborn Errors of Metabolism.菌群失调、宿主代谢与非传染性疾病：先天性代谢缺陷中的三方对话

Front Physiol. 2021 Sep 6;12:716520. doi: 10.3389/fphys.2021.716520. eCollection 2021.

Immunobiotics Beneficially Modulate TLR4 Signaling Triggered by Lipopolysaccharide and Reduce Hepatic Steatosis In Vitro.免疫生物制剂通过调节脂多糖触发的 TLR4 信号通路，减少体外肝脂肪变性。

J Immunol Res. 2019 Mar 14;2019:3876896. doi: 10.1155/2019/3876896. eCollection 2019.

Mosapride Stabilizes Intestinal Microbiota to Reduce Bacterial Translocation and Endotoxemia in CCl-Induced Cirrhotic Rats.莫沙必利可稳定肠道微生物群，以减少四氯化碳诱导的肝硬化大鼠的细菌移位和内毒素血症。

Dig Dis Sci. 2017 Oct;62(10):2801-2811. doi: 10.1007/s10620-017-4704-x. Epub 2017 Aug 16.

The Gastrointestinal Microbiome: Alcohol Effects on the Composition of Intestinal Microbiota.胃肠道微生物群：酒精对肠道微生物群组成的影响

Alcohol Res. 2015;37(2):223-36.

Lactobacillus rhamnosus CCFM1107 treatment ameliorates alcohol-induced liver injury in a mouse model of chronic alcohol feeding.鼠李糖乳杆菌CCFM1107治疗可改善慢性酒精喂养小鼠模型中酒精诱导的肝损伤。

J Microbiol. 2015 Dec;53(12):856-63. doi: 10.1007/s12275-015-5239-5. Epub 2015 Dec 2.

Gut microbiota in alcoholic liver disease: pathogenetic role and therapeutic perspectives.酒精性肝病中的肠道微生物群：致病作用及治疗前景

World J Gastroenterol. 2014 Nov 28;20(44):16639-48. doi: 10.3748/wjg.v20.i44.16639.

Is there a role for probiotics in liver disease?益生菌在肝脏疾病中能发挥作用吗？

ScientificWorldJournal. 2014;2014:874768. doi: 10.1155/2014/874768. Epub 2014 Nov 11.

Lactobacillus rhamnosus GG culture supernatant ameliorates acute alcohol-induced intestinal permeability and liver injury.鼠李糖乳杆菌 GG 培养上清液改善急性酒精诱导的肠道通透性和肝损伤。

Am J Physiol Gastrointest Liver Physiol. 2012 Jul;303(1):G32-41. doi: 10.1152/ajpgi.00024.2012. Epub 2012 Apr 26.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验